Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

PTC Therapeutics Inc. : PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING

06/21/2013 | 05:03am US/Eastern

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT PTC THERAPEUTICS, INC.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.

CONTACT

Jane Baj

PTC Therapeutics, Inc.

908-912-9167

jbaj@ptcbio.com

Sheryl Seapy

Pure Communications

sheryl@purecommunicationsinc.com


distributed by
React to this article
Latest news
Date Title
01:40a BEAZLEY : *bernstein raises beazley plc price target to 370 (360) pence - 'market-perform'
01:38a VOESTALPINE : Ad-hoc News regarding 3rd quarter FY 2015/16
01:38a MANZ : 10 February 2016 Manz AG Starts 2016 with Good Level of Incoming Orders
01:38a VOESTALPINE : defies economic headwinds: higher earnings after the first nine months of the business year 2015/16
01:38a JOHN WILEY & SONS : Wiley and ASLO partner on a new open access journal to integrate limnology and oceanography
01:33a SUBARU : Bainbridge blotter | Hit-and-run driver says ‘no big deal'
01:33a PANORO ENERGY ASA : Information on the Subsequent Offering
01:33a AURUBIS : confirms forecast for the entire fiscal year
01:31a NORDAX : Year-End Report 2015
01:31a TRAINERS' HOUSE GROU : FINANCIAL STATEMENTS BULLETIN FOR 1 JANUARY – 31 DECEMBER 2015
Latest news
Advertisement
Hot News 
BELDEN : Defense in Depth Cyber Security for Substation Communications
FORTIS : ITC HOLDINGS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ITC Holdings Corp.
Viacom CEO Defends His Leadership -- 2nd Update
REDROW : Robust Redrow reports record revenue, profit and growing order book
PROSPECT CAPITAL : reports 2Q loss
Most Read News
02/09 AUSTRALIAN GREENS : Up to 23 consignments of produce sent overseas from farm linked to salmonella outbreak
02/09 CLIFFORD CHANCE LLP : advises on sale of the Isaac Plains Coal Project by Sumitomo Corporation and Vale
02/09 CTI BioPharma Provides Update On Clinical Hold Of Investigational Agent Pacritinib And New Drug Application In U.S.
02/09 VIVA ENERGY AUSTRALIA : Shell Helix DJR Team Penske Sponsorship
02/09 Uber, Slack and Samsung Stole the Show at TechCrunch’s 9th Annual Crunchies Awards
Most recommended articles
01:04a Twitter results need to wow to reassure investors
01:02a Nikkei falls to lowest since Oct 2014 as stress in banking sector lingers
01:01aDJWhy Declining Chinese Oil Production Is Good for Global Prices
12:35aDJYen Stronger Against Rivals as Nikkei Falls Further
12:24a Asahi to buy two SABMiller brands for over $3.5 billion - Nikkei